Nalmexone

Nalmexone
Clinical data
ATC code	None;
Identifiers
	IUPAC name (5α)-3,14-dihydroxy-17-(3-methyl-2-buten-1-yl)-4,5-epoxymorphinan-6-one;
CAS Number	16676-26-9 ; 16291-05-7 (HCl);
PubChem CID	5360516;
ChemSpider	4514525;
UNII	AIB278UKIG;
CompTox Dashboard (EPA)	DTXSID80168172 ;
Chemical and physical data
Formula	C21H25NO4
Molar mass	355.434 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4[C@@H]5Oc1c2c(ccc1O)C[C@H]3N(CC[C@]25[C@@]3(O)CC4)C\C=C(/C)C;
	InChI InChI=1S/C21H25NO4/c1-12(2)6-9-22-10-8-20-17-13-3-4-14(23)18(17)26-19(20)15(24)5-7-21(20,25)16(22)11-13/h3-4,6,16,19,23,25H,5,7-11H2,1-2H3/t16-,19+,20+,21-/m1/s1; Key:OHKCLOQPSLQCQR-MBPVOVBZSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Nalmexone (INN; also known as nalmexone hydrochloride (USAN) or by the development codes EN-1620A and UM-592) is a semisynthetic, opioid partial agonist or mixed agonist-antagonist with both analgesic and narcotic antagonist properties that was never marketed.^[1]^[2]^[3]^[4] In clinical studies it was found to have comparable analgesic efficacy to morphine, though with several-fold reduced potency.^[5] In addition, nalmexone's side effects, the most common of which were sleepiness and sweating, were reported to be similar to those of morphine, albeit with a noticeably higher degree of incidence.^[5]

Synthesis

Nalmexone can be synthesized from oxymorphone:^[6]

References

^ Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1395. ISBN 978-0-412-46630-4. Retrieved 11 May 2012.
^ Casy AF, Parfitt RT (1986). Opioid Analgesics: Chemistry and Receptors. Springer. p. 55. ISBN 978-0-306-42130-3. Retrieved 11 May 2012.
^ Loew GH, Berkowitz DS (1978). "Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics". Journal of Medicinal Chemistry. 21 (1): 101–106. doi:10.1021/jm00199a018. PMID 73588.
^ Forrest WH, Shroff PF, Mahler DL (1972). "Analgesic and other effects of nalmexone in man". Clinical Pharmacology and Therapeutics. 13 (4): 520–525. doi:10.1002/cpt1972134520. PMID 4557582. S2CID 30780581.
^ ^a ^b Committee on Problems of Drug Dependence (1969). Bulletin, problems of drug dependence. National Academies. p. 5873. NAP:10503. Retrieved 11 May 2012.
^ Lowenstein, M. J.; Fishman, J.; 1967, U.S. patent 3,320,262

[Macdonald1997-1] Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1395. ISBN 978-0-412-46630-4. Retrieved 11 May 2012.

[CasyParfitt1986-2] Casy AF, Parfitt RT (1986). Opioid Analgesics: Chemistry and Receptors. Springer. p. 55. ISBN 978-0-306-42130-3. Retrieved 11 May 2012.

[pmid73588-3] Loew GH, Berkowitz DS (1978). "Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics". Journal of Medicinal Chemistry. 21 (1): 101–106. doi:10.1021/jm00199a018. PMID 73588.

[pmid4557582-4] Forrest WH, Shroff PF, Mahler DL (1972). "Analgesic and other effects of nalmexone in man". Clinical Pharmacology and Therapeutics. 13 (4): 520–525. doi:10.1002/cpt1972134520. PMID 4557582. S2CID 30780581.

[DependenceDependence1969-5] Committee on Problems of Drug Dependence (1969). Bulletin, problems of drug dependence. National Academies. p. 5873. NAP:10503. Retrieved 11 May 2012.

[6] Lowenstein, M. J.; Fishman, J.; 1967, U.S. patent 3,320,262

[1]

[2]

[3]

[4]

[5]

[6]

Synthesis

See also

References